Outcomes (time to first event) of patients with CAD (adjusted)
| Outcome | Placebo (n=717) | Nebivolol (n=735) | HR | ||||||
| n | % | AR | n | % | AR | HR | 95% CI | p Value | |
| Primary endpoint | 114 | 15.9 | 9.7 | 79 | 10.7 | 6.5 | 0.68 | 0.51 to 0.90 | 0.008 |
| Sudden death | 64 | 8.9 | 5.3 | 40 | 5.4 | 3.2 | 0.62 | 0.41 to 0.92 | 0.017 |
| Hospitalisation or death (acute MI or unstable angina) | 60 | 8.4 | 5.1 | 45 | 6.1 | 3.7 | 0.74 | 0.50 to 1.09 | 0.12 |
Number (n) and percentage (%) of patients with at least one event.
Annual rate (AR) as number of events per 100 patient-years of follow-up at risk.
HR was calculated based on time-to-event. Analyses adjusted by gender, age and left ventricular ejection fraction.
CAD, coronary artery disease; MI, myocardial infarction.